Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis

BACKGROUND: Infliximab, a chimeric, monoclonal, anti-TNF antibody has been shown to be safe and efficacious for refractory sarcoidosis, we investigated whether adalimumab, a fully human, anti-TNF monoclonal antibody, is similarly safe and efficacious in refractory pulmonary sarcoidosis. METHODS: An...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sweiss, Nadera J., Noth, Imre, Mirsaeidi, Mehdi, Zhang, Wei, Naureckas, Edward T., Hogarth, D. Kyle, Strek, Mary, Caligiuri, Philip, Machado, Roberto F, Niewold, Timothy B, Garcia, Joe G.N., Pangan, Aileen L., Baughman, Robert P.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4134103/
https://ncbi.nlm.nih.gov/pubmed/24751453
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge